

Adrian G Mcnicholl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3115465/publications.pdf>

Version: 2024-02-01

56
papers

2,453
citations

257357

24
h-index

197736

49
g-index

59
all docs

59
docs citations

59
times ranked

2540
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 89-98.	2.4	62
2	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 GastroenterologÃa Y HepatologÃa, 2020, 43, 117-125.	0.2	6
3	A quick flow cytometry protocol to assess <i>Helicobacter pylori</i> viability. <i>Journal of Microbiological Methods</i> , 2020, 177, 106043.	0.7	5
4	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 117-125.	0.0	0
5	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>GastroenterologÃa Y HepatologÃa</i> , 2020, 43, 79-86.	0.2	0
6	Alertas sobre la seguridad de las quinolonas: Â¿debemos modificar su prescripciÃ³n en el tratamiento de la infecciÃ³n por <i>Helicobacter pylori</i> . <i>GastroenterologÃa Y HepatologÃa</i> , 2019, 42, 461-463.	0.2	3
7	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hpâ€uReg). <i>Helicobacter</i> , 2019, 24, e12630.	1.6	46
8	Warnings on the safety of quinolones: Should <i>Helicobacter pylori</i> treatment prescriptions be modified?. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2019, 42, 461-463.	0.0	0
9	Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019, 24, e12593.	1.6	18
10	Metaâ€analysis of threeâ€single capsule bismuthâ€containing quadruple therapy for the eradication of <i>Helicobacter pylori</i>. <i>Helicobacter</i> , 2019, 24, e12570.	1.6	57
11	Empirical <i>Helicobacter pylori</i> rescue therapy: an 18â€year singleâ€centre study of 1200 patients. <i>GastroHep</i> , 2019, 1, 311-324.	0.3	12
12	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2822-2823.	2.4	1
13	Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, doubleâ€blind, placeboâ€controlled trial. <i>Helicobacter</i> , 2018, 23, e12529.	1.6	34
14	Optimization strategies aimed to increase the efficacy of <i>H.Âpylori</i> eradication therapies. <i>Helicobacter</i> , 2017, 22, e12392.	1.6	69
15	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for <i>Helicobacter pylori</i> Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 765-776.	4.9	23
16	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 HepatologÃa, 2017, 40, 658-662.	0.2	11
17	Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. <i>American Journal of Gastroenterology</i> , 2017, 112, 1761-1764.	0.2	16
18	<i>Helicobacter pylori</i> treatment results in Slovenia in the period 2013-2015 as a part of European Registry on <i>Helicobacter pylori</i> Management. <i>Radiology and Oncology</i> , 2017, 52, 1-6.	0.6	9

#	ARTICLE	IF	CITATIONS
19	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 697-721.	0.0	27
20	In<i>H. pylori</i>- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. Evidence-Based Medicine, 2016, 21, 144-144.	0.6	1
21	IV Conferencia EspaÃola de Consenso sobre el tratamiento de la infecciÃ³n por Helicobacter pylori. GastroenterologÃa Y HepatologÃa, 2016, 39, 697-721.	0.2	97
22	Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. The Cochrane Library, 2016, , CD009034.	1.5	35
23	Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine, 2016, 33, 1-2.	1.0	0
24	Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and Liver Disease, 2015, 47, 108-113.	0.4	22
25	Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy. Digestive Diseases and Sciences, 2015, 60, 458-464.	1.1	42
26	Systematic review with meta-analysis: the efficacy of a second anti-â€œTNFâ€œ in patients with inflammatory bowel disease whose previous anti-â€œTNFâ€œ treatment has failed. Alimentary Pharmacology and Therapeutics, 2015, 41, 613-623.	1.9	266
27	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Alimentary Pharmacology and Therapeutics, 2015, 41, 768-775.	1.9	91
28	Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 104-105.	0.8	1
29	Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 105-106.	0.8	1
30	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European Journal of Gastroenterology and Hepatology, 2014, 26, 941-948.	0.8	54
31	Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection. Digestive Diseases and Sciences, 2014, 59, 383-389.	1.1	48
32	Randomised clinical trial comparing sequential and concomitant therapies for<i>Helicobacter pylori</i> eradication in routine clinical practice. Gut, 2014, 63, 244-249.	6.1	119
33	Su1171 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple â€œSequentialâ€œ or â€œConcomitantâ€œ Treatment to Eradicate H. pylori Infection. Gastroenterology, 2014, 146, S-394.	0.6	5
34	Optimum second-line regimens for Helicobacter pylori eradication. The Cochrane Library, 2014, , .	1.5	1
35	Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. European Journal of Medicinal Chemistry, 2013, 68, 284-290.	2.6	17
36	Sa1916 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple â€œSequentialâ€œ or â€œConcomitantâ€œ Treatment to Eradicate H. pylori Infection. Gastroenterology, 2013, 144, S-334.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Sa1891 <i>Helicobacter pylori</i> Activates CD277, a New Co-Inhibitory Molecule. <i>Gastroenterology</i> , 2013, 144, S-328.	0.6	0
38	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	73
39	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple or concomitant treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 652-656.	0.6	32
40	Methotrexate in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1086-1091.	0.8	26
41	Maintenance of <i>Helicobacter pylori</i> Eradication Rates with Triple Therapy Over 12 Years in a Spanish hospital. <i>Helicobacter</i> , 2012, 17, 160-161.	1.6	12
42	Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 414-425.	1.9	165
43	Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2011, 140, S-880.	0.6	0
44	Meta-Analysis: Rabeprazole and Esomeprazole in the Eradication of <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2011, 140, S-880.	0.6	2
45	Amoxicillin Gastric Retention Systems for <i>Helicobacter pylori</i> Treatment. <i>Gastroenterology</i> , 2011, 140, S-880.	0.6	2
46	M1697 Effect of <i>Helicobacter pylori</i> Eradication on Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Randomized Clinical Trials. <i>Gastroenterology</i> , 2010, 138, S-400.	0.6	1
47	M1698 <i>Helicobacter pylori</i> and Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Case-Control Studies. <i>Gastroenterology</i> , 2010, 138, S-401.	0.6	1
48	Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1746-1754.	0.9	97
49	Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1485-1491.	0.9	114
50	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1190-1198.	0.9	265
51	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 126-137.	1.9	186
52	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009, 41, 56-66.	0.4	195
53	M1055 Accuracy of GastroPanel for Non Invasive Diagnosis of Atrophic Gastritis. <i>Gastroenterology</i> , 2009, 136, A-340.	0.6	1
54	S1185 Faecal Calprotectin's Utility in the Prediction of Inflammatory Bowel Disease (IBD) Relapses. <i>Gastroenterology</i> , 2008, 134, A-196.	0.6	0

#	ARTICLE	IF	CITATIONS
55	S1186 The Diagnostic Accuracy of Faecal Calprotectin in Inflammatory Bowel Disease (IBD): A Systematic Review. <i>Gastroenterology</i> , 2008, 134, A-196-A-197.	0.6	1
56	M1095 Empirical Rescue Therapy After <i>H. pylori</i> Treatment Failure: A 10-Year Single Center Study of 500 Patients. <i>Gastroenterology</i> , 2008, 134, A-337.	0.6	0